The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study

American Heart Journal

Volumn 169, Issue 5, 2015, Pages 736-742.e1

  Hovingh, G Kees ^a   Smits, Loek P ^a   Stefanutti, Claudia ^b   Soran, Handrean ^c   Kwok, See ^c   De Graaf, Jacqueline ^d   Gaudet, Daniel ^e   Keyserling, Constance H ^f   Klepp, Heather ^f   Frick, Jennifer ^f   Paolini, John F ^f   Dasseux, Jean Louis ^f   Kastelein, John J P ^a   Stroes, Erik S ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Cerenis Therapeutics Holdings   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; CER 001; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; KEXIN; KEXIN TYPE 9; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR ADAPTOR PROTEIN 1; UNCLASSIFIED DRUG; CER-001; PHOSPHOLIPID; RECOMBINANT PROTEIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL WALL; CAROTID ARTERY; CLINICAL ARTICLE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIPID BLOOD LEVEL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING; URTICARIA; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; PATHOLOGY; RARE DISEASE;

ADULT; APOLIPOPROTEIN A-I; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; RARE DISEASES; RECOMBINANT PROTEINS;

EID: 84929266768     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.01.008     Document Type: Article

References (34)

1. B. Sjouke, D.M. Kusters, and I. Kindt Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome Eur Heart J 36 9 2014 560 565
2. J.L. Goldstein, H.G. Schrott, and W.R. Hazzard Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia J Clin Invest 52 1973 1544 1568
3. F.J. Raal, G.J. Pilcher, and V.R. Panz Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy Circulation 124 2011 2202 2207
4. G.R. Thompson, M. Barbir, and K. Okabayashi Plasmapheresis in familial hypercholesterolemia Arteriosclerosis 9 1989 I152 I157
5. F. Raal, R. Scott, and R. Somaratne Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibiti Circulation 126 20 2012 2408 2417
6. C.M. Perry Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia Am J Cardiovasc Drugs 13 2013 285 296
7. D.J. Rader, and J.J.P. Kastelein Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia Circulation 129 2014 1022 1032
8. F.J. Raal, N. Honarpour, and D.J. Blom Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 385 9965 2015 341 350
9. D.J. Rader, and G.K. Hovingh HDL and cardiovascular disease Lancet 384 2014 618 625
10. C. Tardy, M. Goffinet, and N. Boubekeur CER-001, an HDL-mimetic, Stimulates the Reverse Lipid Transport and Atherosclerosis regression in High Cholesterol Diet-fed LDL-Receptor Deficient Mice Atherosclerosis 232 1 2014 110 118
11. M. Eriksson, L.A. Carlson, and T.A. Miettinen Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans Circulation 100 1999 594 598
12. J.A. Shaw, A. Bobik, and A. Murphy Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque Circ Res 103 2008 1084 1091
13. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
14. J.-C. Tardif, J. Grégoire, and P.L. L'Allier Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial JAMA 297 2007 1675 1682
15. J.-C. Tardif, C.M. Ballantyne, and P. Barter Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: A randomized trial Eur Heart J 35 46 2014 3277 3286
16. R. Waksman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
17. R. Duivenvoorden, A.G. Holleboom, and B. van den Bogaard Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected] J Am Coll Cardiol 58 2011 2481 2487
18. R. Corti, V. Fuster, and Z.A. Fayad Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging J Am Coll Cardiol 46 2005 106 112
19. R.Q. Migrino, M. Bowers, and L. Harmann Carotid plaque regression following 6-month statin therapy assessed by 3 T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness J Cardiovasc Magn Reson 13 2011 37
20. M. Hellerstein, and S. Turner Reverse cholesterol transport fluxes Curr Opin Lipidol 25 2014 40 47
21. L.R.C. Martinez, R.D. Santos, and M.H. Miname Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia Metabolism 62 2013 1061 1064
22. N. Bellanger, A. Orsoni, and Z. Julia Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia Arterioscler Thromb Vasc Biol 31 2011 1675 1681
23. L.P. Smits, R.S. Kootte, and E.S. Stroes Reversal of atherosclerosis with apolipoprotein A1: Back to basics Atherosclerosis 232 2014 217 219
24. R. Duivenvoorden, E. de Groot, and B.M. Elsen In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging Circ Cardiovasc Imaging 2 2009 235 242
25. R.S. Kootte, L.P. Smits, and F.M. van der Valk Effect of open-label infusion of an apolipoprotein A-I-containing particle (CER-001) on reverse cholesterol transport and artery wall thickness in patients with familial hypo-alphalipoproteinemia J Lipid Res 56 3 2015 703 712
26. R.J. Bisoendial, G.K. Hovingh, and J.H.M. Levels Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein Circulation 107 2003 2944 2948
27. J.R. Crouse, R.P. Byington, and M.G. Bond Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II) Am J Cardiol 75 1995 455 459
28. H.N. Hodis, W.J. Mack, and L. LaBree Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial Ann Intern Med 124 1996 548 556
29. S. MacMahon, N. Sharpe, and G. Gamble Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group Circulation 97 1998 1784 1790
30. E. De Groot, J.W. Jukema, and A.D. Montauban van Swijndregt B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS) J Am Coll Cardiol 31 1998 1561 1567
31. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
32. T.J. Smilde, S. van Wissen, and H. Wollersheim Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 2001 577 581
33. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
34. A.E.H. Zavodni, B.A. Wasserman, and R.L. McClelland Carotid artery plaque morphology and composition in relation to incident cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA) Radiology 271 2014 381 389